Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Blood|June 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD preventionJoseph A Pidala, Nicoletta Cieri, Michael J Schell, et al.
Blood Cancer Journal|October 16, 2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaGliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Haematologica|July 14, 2022
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Jeremy Ramdial, Mazyar Shadman, et al.
Transplantation and Cellular Therapy|April 27, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell LymphomaRoni Shouval, Christopher Strouse, Soyoung Kim, et al.
Blood|April 21, 2025
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell TherapyKai Rejeski, Jaime Sanz, Teng Fei, et al.
Blood Cancer Discovery|May 9, 2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell LymphomaNeeraj Y Saini, David M Swoboda, Uri Greenbaum, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Transplantation and Cellular Therapy|December 20, 2025
Safety and efficacy of tumor-infiltrating lymphocyte (TIL) therapy with reduced-dose lymphodepleting conditioning in high-risk metastatic melanoma patientsLilit Karapetyan, Joel Kuriakose, Elizabeth DiMaggio, et al.
Blood|June 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD preventionJoseph A Pidala, Nicoletta Cieri, Michael J Schell, et al.
Blood Cancer Journal|October 16, 2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaGliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
Haematologica|July 14, 2022
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Jeremy Ramdial, Mazyar Shadman, et al.
Transplantation and Cellular Therapy|April 27, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell LymphomaRoni Shouval, Christopher Strouse, Soyoung Kim, et al.
Blood|April 21, 2025
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell TherapyKai Rejeski, Jaime Sanz, Teng Fei, et al.
Blood Cancer Discovery|May 9, 2022
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell LymphomaNeeraj Y Saini, David M Swoboda, Uri Greenbaum, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
Blood Cancer Journal|March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy ConsortiumAndrew J Portuguese, James A Davis, Shahzad Raza, et al.
Pageof 20